Inhibitory Effect of Diosgenin on Experimentally Induced Benign Prostatic Hyperplasia in Rats

This study investigated the effect of diosgenin,a natural sapogenin possessing various pharmacological activities,on benign prostatic hyperplasia(BPH) in rats and the possible mechanisms.BPH was established in the castrated rats by subcutaneous injection of testosterone propionate.Animals were rando...

Full description

Saved in:
Bibliographic Details
Published inJournal of Huazhong University of Science and Technology. Medical sciences Vol. 36; no. 6; pp. 806 - 810
Main Author 陈静 章怀奋 熊朝梅 阮金兰
Format Journal Article
LanguageEnglish
Published Wuhan Huazhong University of Science and Technology 01.12.2016
Department of Pharmacy, the First People's Hospital of Yueyang, Yueyang 414000, China%School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
Subjects
Online AccessGet full text
ISSN1672-0733
1993-1352
1993-1352
DOI10.1007/s11596-016-1666-8

Cover

Abstract This study investigated the effect of diosgenin,a natural sapogenin possessing various pharmacological activities,on benign prostatic hyperplasia(BPH) in rats and the possible mechanisms.BPH was established in the castrated rats by subcutaneous injection of testosterone propionate.Animals were randomly divided into four groups(n=10 each):model group(0.5% sodium carboxymethyl cellulose);positive control group(3 mg/kg finasteride);two diosgenin groups(50 and 100 mg/kg).The drugs were intragastricaly given in each group for consecutive 3 weeks.Another 10 rats with no testicles cut off served as negative controls and they were subcutaneously injected with 0.1 m L olive oil per day and then treated with 0.5% sodium carboxymethylcellulose.After 3-week administration,the prostate index and serum PSA level were determined,and histopathological examination was carried out.The levels of MDA,SOD and GPx in prostates were also measured.Additionally,the expression of Bcl-2,Bax and p53 was examined using Western blotting.The results showed that the prostate index and serum PSA level were significantly decreased,and the pathological changes of the prostate gland were greatly improved in diosgenin groups as compared with the model group.Elevated activities of SOD and GPx,and reduced MDA level were also observed in diosgenin-treated rats.In addition,the expression of Bcl-2 in prostates was down-regulated,whereas that of Bax and p53 was up-regulated in diosgenin-treated rats.These results indicated that diosgenin was effective in inhibiting testosterone propionate-induced prostate enlargement and may be a candidate agent for the treatment of BPH.
AbstractList This study investigated the effect of diosgenin, a natural sapogenin possessing various pharmacological activities, on benign prostatic hyperplasia (BPH) in rats and the possible mechanisms. BPH was established in the castrated rats by subcutaneous injection of testosterone propionate. Animals were randomly divided into four groups (n=10 each): model group (0.5% sodium carboxymethyl cellulose); positive control group (3 mg/kg finasteride); two diosgenin groups (50 and 100 mg/kg). The drugs were intragastricaly given in each group for consecutive 3 weeks. Another 10 rats with no testicles cut off served as negative controls and they were subcutaneously injected with 0.1 mL olive oil per day and then treated with 0.5% sodium carboxymethylcellulose. After 3-week administration, the prostate index and serum PSA level were determined, and histopathological examination was carried out. The levels of MDA, SOD and GPx in prostates were also measured. Additionally, the expression of Bcl-2, Bax and p53 was examined using Western blotting. The results showed that the prostate index and serum PSA level were significantly decreased, and the pathological changes of the prostate gland were greatly improved in diosgenin groups as compared with the model group. Elevated activities of SOD and GPx, and reduced MDA level were also observed in diosgenin-treated rats. In addition, the expression of Bcl-2 in prostates was down-regulated, whereas that of Bax and p53 was up-regulated in diosgenin-treated rats. These results indicated that diosgenin was effective in inhibiting testosterone propionate-induced prostate enlargement and may be a candidate agent for the treatment of BPH.
This study investigated the effect of diosgenin, a natural sapogenin possessing various pharmacological activities, on benign prostatic hyperplasia (BPH) in rats and the possible mechanisms. BPH was established in the castrated rats by subcutaneous injection of testosterone propionate. Animals were randomly divided into four groups ( n =10 each): model group (0.5% sodium carboxymethyl cellulose); positive control group (3 mg/kg finasteride); two diosgenin groups (50 and 100 mg/kg). The drugs were intragastricaly given in each group for consecutive 3 weeks. Another 10 rats with no testicles cut off served as negative controls and they were subcutaneously injected with 0.1 mL olive oil per day and then treated with 0.5% sodium carboxymethylcellulose. After 3-week administration, the prostate index and serum PSA level were determined, and histopathological examination was carried out. The levels of MDA, SOD and GPx in prostates were also measured. Additionally, the expression of Bcl-2, Bax and p53 was examined using Western blotting. The results showed that the prostate index and serum PSA level were significantly decreased, and the pathological changes of the prostate gland were greatly improved in diosgenin groups as compared with the model group. Elevated activities of SOD and GPx, and reduced MDA level were also observed in diosgenin-treated rats. In addition, the expression of Bcl-2 in prostates was down-regulated, whereas that of Bax and p53 was up-regulated in diosgenin-treated rats. These results indicated that diosgenin was effective in inhibiting testosterone propionate-induced prostate enlargement and may be a candidate agent for the treatment of BPH.
This study investigated the effect of diosgenin, a natural sapogenin possessing various pharmacological activities, on benign prostatic hyperplasia (BPH) in rats and the possible mechanisms. BPH was established in the castrated rats by subcutaneous injection of testosterone propionate. Animals were randomly divided into four groups (n=10 each): model group (0.5% sodium carboxymethyl cellulose); positive control group (3 mg/kg finasteride); two diosgenin groups (50 and 100 mg/kg). The drugs were intragastricaly given in each group for consecutive 3 weeks. Another 10 rats with no testicles cut off served as negative controls and they were subcutaneously injected with 0.1 mL olive oil per day and then treated with 0.5% sodium carboxymethylcellulose. After 3-week administration, the prostate index and serum PSA level were determined, and histopathological examination was carried out. The levels of MDA, SOD and GPx in prostates were also measured. Additionally, the expression of Bcl-2, Bax and p53 was examined using Western blotting. The results showed that the prostate index and serum PSA level were significantly decreased, and the pathological changes of the prostate gland were greatly improved in diosgenin groups as compared with the model group. Elevated activities of SOD and GPx, and reduced MDA level were also observed in diosgenin-treated rats. In addition, the expression of Bcl-2 in prostates was down-regulated, whereas that of Bax and p53 was up-regulated in diosgenin-treated rats. These results indicated that diosgenin was effective in inhibiting testosterone propionate-induced prostate enlargement and may be a candidate agent for the treatment of BPH.This study investigated the effect of diosgenin, a natural sapogenin possessing various pharmacological activities, on benign prostatic hyperplasia (BPH) in rats and the possible mechanisms. BPH was established in the castrated rats by subcutaneous injection of testosterone propionate. Animals were randomly divided into four groups (n=10 each): model group (0.5% sodium carboxymethyl cellulose); positive control group (3 mg/kg finasteride); two diosgenin groups (50 and 100 mg/kg). The drugs were intragastricaly given in each group for consecutive 3 weeks. Another 10 rats with no testicles cut off served as negative controls and they were subcutaneously injected with 0.1 mL olive oil per day and then treated with 0.5% sodium carboxymethylcellulose. After 3-week administration, the prostate index and serum PSA level were determined, and histopathological examination was carried out. The levels of MDA, SOD and GPx in prostates were also measured. Additionally, the expression of Bcl-2, Bax and p53 was examined using Western blotting. The results showed that the prostate index and serum PSA level were significantly decreased, and the pathological changes of the prostate gland were greatly improved in diosgenin groups as compared with the model group. Elevated activities of SOD and GPx, and reduced MDA level were also observed in diosgenin-treated rats. In addition, the expression of Bcl-2 in prostates was down-regulated, whereas that of Bax and p53 was up-regulated in diosgenin-treated rats. These results indicated that diosgenin was effective in inhibiting testosterone propionate-induced prostate enlargement and may be a candidate agent for the treatment of BPH.
This study investigated the effect of diosgenin,a natural sapogenin possessing various pharmacological activities,on benign prostatic hyperplasia(BPH) in rats and the possible mechanisms.BPH was established in the castrated rats by subcutaneous injection of testosterone propionate.Animals were randomly divided into four groups(n=10 each):model group(0.5% sodium carboxymethyl cellulose);positive control group(3 mg/kg finasteride);two diosgenin groups(50 and 100 mg/kg).The drugs were intragastricaly given in each group for consecutive 3 weeks.Another 10 rats with no testicles cut off served as negative controls and they were subcutaneously injected with 0.1 m L olive oil per day and then treated with 0.5% sodium carboxymethylcellulose.After 3-week administration,the prostate index and serum PSA level were determined,and histopathological examination was carried out.The levels of MDA,SOD and GPx in prostates were also measured.Additionally,the expression of Bcl-2,Bax and p53 was examined using Western blotting.The results showed that the prostate index and serum PSA level were significantly decreased,and the pathological changes of the prostate gland were greatly improved in diosgenin groups as compared with the model group.Elevated activities of SOD and GPx,and reduced MDA level were also observed in diosgenin-treated rats.In addition,the expression of Bcl-2 in prostates was down-regulated,whereas that of Bax and p53 was up-regulated in diosgenin-treated rats.These results indicated that diosgenin was effective in inhibiting testosterone propionate-induced prostate enlargement and may be a candidate agent for the treatment of BPH.
Author 陈静 章怀奋 熊朝梅 阮金兰
AuthorAffiliation Department of Pharmacy, the First People's Hospital of Yueyang, Yueyang 414000, China School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
AuthorAffiliation_xml – name: Department of Pharmacy, the First People's Hospital of Yueyang, Yueyang 414000, China%School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
Author_xml – sequence: 1
  fullname: 陈静 章怀奋 熊朝梅 阮金兰
BackLink https://www.ncbi.nlm.nih.gov/pubmed/27924509$$D View this record in MEDLINE/PubMed
BookMark eNqNkV1rFDEUhoNU7If-AG8keCWU0XxNJrnUutqFgiJ6KSEzSaZZZ5PtJIM7_75ZZq3gRfEqgTxvzuF5z8FJiMEC8BKjtxih5l3CuJa8QphXmHNeiSfgDEtJK0xrclLuvCEVaig9BecpbRCqG07YM3BKGklYjeQZ-LkOt771OY4zXDlnuwyjgx99TL0NPsAY4Gq_s6Pf2pD1MMxwHczUWQM_lPc-wK9jTFln38HruXC7QSevYUl-0zk9B0-dHpJ9cTwvwI9Pq-9X19XNl8_rq_c3VccYylVthay5kYJKijtRt8yYlmttLJHasFYSR7kRmKKOtI0lDXZCOIsk5gzVyNELcLn8-1sHp0OvNnEaQ5mo8mb-Zfb7VllSNCFeHBT6zULvxng32ZTV1qfODoMONk5JYSGE5AKz_0FZcYxqQgv66ohO7dYatSvO9DirP64LgBegK8rSaN0DgpE69KmWPlVZVB36VKJkmn8ynT_YjiGP2g-PJsmSTGVK6O3418ljodfHcbcx9Hcl97AjbzBmRDJO7wG23L5d
CitedBy_id crossref_primary_10_3390_biomedicines12081636
crossref_primary_10_1016_j_sajb_2020_04_009
crossref_primary_10_1016_j_biopha_2017_03_020
crossref_primary_10_1007_s11101_020_09661_0
crossref_primary_10_1186_s43094_021_00318_z
crossref_primary_10_1177_0960327119889655
crossref_primary_10_1016_j_reprotox_2024_108647
crossref_primary_10_1111_fcp_12384
crossref_primary_10_2147_RRU_S478740
crossref_primary_10_1002_tox_22876
crossref_primary_10_1016_j_bbrep_2018_03_005
crossref_primary_10_1016_j_molstruc_2018_12_009
Cites_doi 10.1016/j.phytochem.2006.10.026
10.1007/s12291-012-0229-4
10.1007/s11596-014-1278-0
10.1155/2014/475876
10.1023/A:1006118628183
10.1002/(SICI)1097-0045(20000401)43:1<49::AID-PROS7>3.0.CO;2-J
10.1159/000315064
10.3390/ijms140714301
10.1016/S0022-5347(01)64536-1
10.1021/np500810c
10.1016/j.ejphar.2014.07.026
10.1016/j.toxlet.2013.03.002
10.1016/j.juro.2010.11.060
10.1016/j.etap.2014.02.001
10.1016/S0046-8177(96)90396-2
10.1371/journal.pone.0020164
10.1016/j.ejphar.2012.10.028
10.1111/bju.12118
10.1517/14728214.11.1.111
10.1016/S0090-4295(03)00589-2
10.1186/1423-0127-21-19
10.1126/science.281.5381.1322
10.1089/jmf.2011.1968
10.1007/s11746-998-0032-9
10.1016/S0022-5347(17)49698-4
ContentType Journal Article
Copyright Huazhong University of Science and Technology and Springer-Verlag Berlin Heidelberg 2016
Copyright © Wanfang Data Co. Ltd. All Rights Reserved.
Copyright_xml – notice: Huazhong University of Science and Technology and Springer-Verlag Berlin Heidelberg 2016
– notice: Copyright © Wanfang Data Co. Ltd. All Rights Reserved.
DBID 2RA
92L
CQIGP
W91
~WA
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
7QO
8FD
FR3
P64
2B.
4A8
92I
93N
PSX
TCJ
DOI 10.1007/s11596-016-1666-8
DatabaseName 维普期刊资源整合服务平台
中文科技期刊数据库-CALIS站点
维普中文期刊数据库
中文科技期刊数据库-医药卫生
中文科技期刊数据库- 镜像站点
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
Biotechnology Research Abstracts
Technology Research Database
Engineering Research Database
Biotechnology and BioEngineering Abstracts
Wanfang Data Journals - Hong Kong
WANFANG Data Centre
Wanfang Data Journals
万方数据期刊 - 香港版
China Online Journals (COJ)
China Online Journals (COJ)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
Engineering Research Database
Biotechnology Research Abstracts
Technology Research Database
Biotechnology and BioEngineering Abstracts
DatabaseTitleList Engineering Research Database

MEDLINE
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate Inhibitory Effect of Diosgenin on Experimentally Induced Benign Prostatic Hyperplasia in Rats
EISSN 1993-1352
EndPage 810
ExternalDocumentID tjykdxxb_e201606005
27924509
10_1007_s11596_016_1666_8
671142946
Genre Journal Article
GrantInformation_xml – fundername: the National Nature Science Foundation of China
  funderid: (81173065)
GroupedDBID -5E
-5G
-BR
-Y2
-~C
.86
.VR
06C
06D
0R~
0VY
1N0
29K
29~
2B.
2C~
2J2
2KG
2KM
2LR
2RA
2~H
30V
4.4
408
40D
40E
53G
5GY
5VS
6NX
8TC
8UJ
92F
92I
92L
95-
95.
95~
96X
AAAVM
AABHQ
AAJKR
AANXM
AARHV
AARTL
AAYIU
AAYQN
AAYTO
ABFTV
ABJNI
ABJOX
ABKCH
ABMNI
ABNWP
ABQBU
ABTMW
ACGFS
ACHXU
ACKNC
ACOMO
ACSNA
ACUDM
ADHIR
ADINQ
ADKPE
ADURQ
ADYFF
ADZKW
AEBTG
AEGNC
AEJHL
AEKMD
AEOHA
AEPYU
AETLH
AEXYK
AFWTZ
AFZKB
AGAYW
AGDGC
AGQMX
AGWIL
AGWZB
AGYKE
AHAVH
AHBYD
AHKAY
AHYZX
AIIXL
AJBLW
AJRNO
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMKLP
ARMRJ
AZFZN
B-.
BA0
BGNMA
CAG
CCEZO
CHBEP
CIEJG
COF
CQIGP
CS3
CSCUP
CW9
D-I
DPUIP
EBS
EJD
ESBYG
FA0
FEDTE
FNLPD
FRRFC
FWDCC
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GQ6
GQ7
HF~
HG6
HMJXF
HRMNR
HVGLF
HZ~
IJ-
IXD
I~X
I~Z
J-C
JBSCW
JUIAU
KOV
M4Y
MA-
N2Q
NDZJH
NQJWS
NU0
O9-
O93
O9I
O9J
P9S
PF0
QOR
QOS
R-E
R89
R9I
RIG
ROL
RPX
RSV
S..
S16
S1Z
S27
S37
S3B
SAP
SCL
SDH
SHX
SMD
SNE
SNX
SOJ
SPISZ
SZ9
SZN
T13
TCJ
TSG
TT1
TUC
U2A
U9L
UG4
VC2
W48
W91
WK8
Z7U
Z82
Z8V
ZOVNA
~A9
~WA
ABQSL
H13
AAYXX
ADHKG
AGQPQ
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
7QO
8FD
FR3
P64
4A8
93N
PSX
ID FETCH-LOGICAL-c440t-5e8956d983931c85b4ddb6aade29ad4b92f36d8130c2b7e271f88fe09164050f3
IEDL.DBID U2A
ISSN 1672-0733
1993-1352
IngestDate Thu May 29 04:06:47 EDT 2025
Tue Oct 07 09:43:07 EDT 2025
Fri Sep 05 13:40:56 EDT 2025
Thu Apr 03 06:58:43 EDT 2025
Wed Oct 01 00:36:02 EDT 2025
Thu Apr 24 23:02:46 EDT 2025
Fri Feb 21 02:37:17 EST 2025
Wed Feb 14 10:05:33 EST 2024
IsPeerReviewed false
IsScholarly false
Issue 6
Keywords apoptosis
diosgenin
benign prostatic hyperplasia
oxidative stress
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c440t-5e8956d983931c85b4ddb6aade29ad4b92f36d8130c2b7e271f88fe09164050f3
Notes diosgenin; benign prostatic hyperplasia; oxidative stress; apoptosis
42-1679/R
Jing CHEN1, Huai-fen ZHANG1, Chao-mei XIONG2, Jin-lan RUAN 2( 1Department of Pharmacy, the First People's Hospital of Yueyang, Yueyang 414000, China; 2School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China)
This study investigated the effect of diosgenin,a natural sapogenin possessing various pharmacological activities,on benign prostatic hyperplasia(BPH) in rats and the possible mechanisms.BPH was established in the castrated rats by subcutaneous injection of testosterone propionate.Animals were randomly divided into four groups(n=10 each):model group(0.5% sodium carboxymethyl cellulose);positive control group(3 mg/kg finasteride);two diosgenin groups(50 and 100 mg/kg).The drugs were intragastricaly given in each group for consecutive 3 weeks.Another 10 rats with no testicles cut off served as negative controls and they were subcutaneously injected with 0.1 m L olive oil per day and then treated with 0.5% sodium carboxymethylcellulose.After 3-week administration,the prostate index and serum PSA level were determined,and histopathological examination was carried out.The levels of MDA,SOD and GPx in prostates were also measured.Additionally,the expression of Bcl-2,Bax and p53 was examined using Western blotting.The results showed that the prostate index and serum PSA level were significantly decreased,and the pathological changes of the prostate gland were greatly improved in diosgenin groups as compared with the model group.Elevated activities of SOD and GPx,and reduced MDA level were also observed in diosgenin-treated rats.In addition,the expression of Bcl-2 in prostates was down-regulated,whereas that of Bax and p53 was up-regulated in diosgenin-treated rats.These results indicated that diosgenin was effective in inhibiting testosterone propionate-induced prostate enlargement and may be a candidate agent for the treatment of BPH.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 27924509
PQID 1846720523
PQPubID 23479
PageCount 5
ParticipantIDs wanfang_journals_tjykdxxb_e201606005
proquest_miscellaneous_1888968145
proquest_miscellaneous_1846720523
pubmed_primary_27924509
crossref_primary_10_1007_s11596_016_1666_8
crossref_citationtrail_10_1007_s11596_016_1666_8
springer_journals_10_1007_s11596_016_1666_8
chongqing_primary_671142946
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2016-12-01
PublicationDateYYYYMMDD 2016-12-01
PublicationDate_xml – month: 12
  year: 2016
  text: 2016-12-01
  day: 01
PublicationDecade 2010
PublicationPlace Wuhan
PublicationPlace_xml – name: Wuhan
– name: China
PublicationSubtitle Medical Sciences
PublicationTitle Journal of Huazhong University of Science and Technology. Medical sciences
PublicationTitleAbbrev J. Huazhong Univ. Sci. Technol. [Med. Sci.]
PublicationTitleAlternate Journal of Zuazhong University of Science and Technology: Medical Edition
PublicationTitle_FL Journal of Huazhong University of Science and Technology(Medical Science)
PublicationYear 2016
Publisher Huazhong University of Science and Technology
Department of Pharmacy, the First People's Hospital of Yueyang, Yueyang 414000, China%School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
Publisher_xml – name: Huazhong University of Science and Technology
– name: Department of Pharmacy, the First People's Hospital of Yueyang, Yueyang 414000, China%School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
References Kaplan, Lee, Meehan (CR6) 2011; 185
Bullock, Andriole (CR8) 2006; 11
Chen, Shih, Huang (CR16) 2011; 6
Ahmad, Suhail, Mansoor (CR21) 2012; 27
Kim, Jeon, Lee (CR15) 2012; 2012
Minutoli, Altavilla, Marini (CR25) 2014; 21
Ahmed, Obaid, Zaki (CR14) 2014; 740
Sirab, Robert, Fasolo (CR11) 2013; 14
Djavan (CR2) 2003; 62
Adams, Cory (CR26) 1998; 281
Chung, Cheon, An (CR10) 2015; 78
Chen, Xiong, Song (CR17) 2012; 15
Shao, Guo, Cui (CR13) 2007; 68
van Coppenolle, Le Bourhis, Carpentier (CR18) 2000; 43
Gandaglia, Briganti, Gontero (CR3) 2013; 112
Aruoma (CR23) 1998; 75
Fleshner, Klotz (CR22) 1999; 17
Carlin, Seftel, Resnick (CR9) 1997; 158
Amaral, Xavier, Steer (CR27) 2010; 9
Roshan, Liu, Banafa (CR28) 2014; 34
Pace, Di Massimo, de Amicis (CR5) 2010; 85
Jang, Bae, Yuk (CR24) 2014; 2014
Ali, Kondreddi, Veeresh (CR19) 2013; 698
Xu, Wang, Mei (CR12) 2014; 37
Kyprianou, Tu, Jacobs (CR4) 1996; 27
Atawia, Tadros, Khalifa (CR20) 2013; 219
Berry, Coffey, Walsh (CR1) 1984; 132
Oelke, Höfner, Berges (CR7) 2002; 41
DS Kim (1666_CR15) 2012; 2012
JM Adams (1666_CR26) 1998; 281
G Pace (1666_CR5) 2010; 85
N Sirab (1666_CR11) 2013; 14
BI Carlin (1666_CR9) 1997; 158
J Chen (1666_CR17) 2012; 15
F Coppenolle van (1666_CR18) 2000; 43
NE Fleshner (1666_CR22) 1999; 17
L Minutoli (1666_CR25) 2014; 21
OI Aruoma (1666_CR23) 1998; 75
PS Chen (1666_CR16) 2011; 6
RT Atawia (1666_CR20) 2013; 219
DH Xu (1666_CR12) 2014; 37
SA Kaplan (1666_CR6) 2011; 185
JD Amaral (1666_CR27) 2010; 9
M Ahmad (1666_CR21) 2012; 27
G Gandaglia (1666_CR3) 2013; 112
MI Ali (1666_CR19) 2013; 698
N Kyprianou (1666_CR4) 1996; 27
SJ Berry (1666_CR1) 1984; 132
B Djavan (1666_CR2) 2003; 62
B Shao (1666_CR13) 2007; 68
LA Ahmed (1666_CR14) 2014; 740
M Oelke (1666_CR7) 2002; 41
S Roshan (1666_CR28) 2014; 34
KS Chung (1666_CR10) 2015; 78
H Jang (1666_CR24) 2014; 2014
TL Bullock (1666_CR8) 2006; 11
10453275 - Cancer Metastasis Rev. 1998-1999;17(4):325-30
23123055 - Eur J Pharmacol. 2013 Jan 5;698(1-3):397-403
23500659 - Toxicol Lett. 2013 May 23;219(2):160-9
21629786 - PLoS One. 2011;6(5):e20164
25062790 - Eur J Pharmacol. 2014 Oct 5;740:379-87
22719792 - Evid Based Complement Alternat Med. 2012;2012:981675
10725865 - Prostate. 2000 Apr 1;43(1):49-58
20484887 - Urol Int. 2010;85(3):328-33
24607683 - Environ Toxicol Pharmacol. 2014 Mar;37(2):679-88
12957195 - Urology. 2003 Sep;62(3 Suppl 1):6-14
24701239 - Evid Based Complement Alternat Med. 2014;2014:475876
22510101 - J Med Food. 2012 Jul;15(7):646-50
9735050 - Science. 1998 Aug 28;281(5381):1322-6
23846725 - Int J Mol Sci. 2013 Jul 10;14(7):14301-20
21334655 - J Urol. 2011 Apr;185(4):1369-73
20193641 - Discov Med. 2010 Feb;9(45):145-52
8698310 - Hum Pathol. 1996 Jul;27(7):668-75
25714330 - J Nat Prod. 2015 Apr 24;78(4):689-94
12426859 - Urologe A. 2002 Sep;41(5):425-41
16503830 - Expert Opin Emerg Drugs. 2006 Mar;11(1):111-23
24082465 - Indian J Clin Biochem. 2012 Oct;27(4):385-8
17166529 - Phytochemistry. 2007 Mar;68(5):623-30
23650937 - BJU Int. 2013 Aug;112(4):432-41
24606563 - J Biomed Sci. 2014 Mar 10;21:19
24939294 - J Huazhong Univ Sci Technolog Med Sci. 2014 Jun;34(3):330-6
9224349 - J Urol. 1997 Aug;158(2):547
6206240 - J Urol. 1984 Sep;132(3):474-9
References_xml – volume: 68
  start-page: 623
  issue: 5
  year: 2007
  end-page: 630
  ident: CR13
  article-title: Steroidal saponins from Smilax china and their anti-inflammatory activities
  publication-title: Phytochemistry
  doi: 10.1016/j.phytochem.2006.10.026
– volume: 27
  start-page: 385
  issue: 4
  year: 2012
  end-page: 388
  ident: CR21
  article-title: Evaluation of oxidative stress and DNA damage in benign prostatic hyperplasia patients and comparison with controls
  publication-title: Indian J Clin Biochem
  doi: 10.1007/s12291-012-0229-4
– volume: 34
  start-page: 330
  issue: 3
  year: 2014
  end-page: 336
  ident: CR28
  article-title: Fucoidan induces apoptosis of HepG2 cells by down-regulating p-Stat3
  publication-title: J Huazhong Univ Sci Technol [Med Sci]
  doi: 10.1007/s11596-014-1278-0
– volume: 2014
  start-page: 475876
  year: 2014
  ident: CR24
  article-title: Seoritae extract reduces prostate weight and suppresses prostate cell proliferation in a rat model of benign prostate hyperplasia
  publication-title: Evid Based Complement Alternat Med
  doi: 10.1155/2014/475876
– volume: 17
  start-page: 325
  issue: 4
  year: 1999
  end-page: 330
  ident: CR22
  article-title: Diet, androgens, oxidative stress and prostate cancer susceptibility
  publication-title: Cancer Metastasis Rev
  doi: 10.1023/A:1006118628183
– volume: 43
  start-page: 49
  issue: 1
  year: 2000
  end-page: 58
  ident: CR18
  article-title: Pharmacological effects of the lipidosterolic extract of Serenoa repens (Permixon®) on rat prostate hyperplasia induced by hyperprolactinemia: comparison with finasteride
  publication-title: Prostate
  doi: 10.1002/(SICI)1097-0045(20000401)43:1<49::AID-PROS7>3.0.CO;2-J
– volume: 85
  start-page: 328
  issue: 3
  year: 2010
  end-page: 333
  ident: CR5
  article-title: Oxidative stress in benign prostatic hyperplasia and prostate cancer
  publication-title: Urol Int
  doi: 10.1159/000315064
– volume: 14
  start-page: 14301
  issue: 7
  year: 2013
  end-page: 14320
  ident: CR11
  article-title: Lipidosterolic extract of Serenoa repens modulates the expression of inflammation related-genes in benign prostatic hyperplasia epithelial and stromal cells
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms140714301
– volume: 158
  start-page: 547
  issue: 2
  year: 1997
  ident: CR9
  article-title: Finasteride induced gynecomastia
  publication-title: J Urol
  doi: 10.1016/S0022-5347(01)64536-1
– volume: 78
  start-page: 689
  issue: 4
  year: 2015
  end-page: 694
  ident: CR10
  article-title: Effects of resveratrol on benign prostatic hyperplasia by the regulation of inflamematory and apoptotic proteins
  publication-title: J Nat Prod
  doi: 10.1021/np500810c
– volume: 740
  start-page: 379
  year: 2014
  end-page: 387
  ident: CR14
  article-title: Role of oxidative stress, inflammation, nitric oxide and transforming growth factor-beta in the protective effect of diosgenin in monocrotalin-induced pulmonary hypertension in rats
  publication-title: Eur J Pharmacol
  doi: 10.1016/j.ejphar.2014.07.026
– volume: 219
  start-page: 160
  issue: 2
  year: 2013
  end-page: 169
  ident: CR20
  article-title: Role of the phytoestrogenic, pro-apoptotic and anti-oxidative properties of silymarin in inhibiting experimental benign prostatic hyperplasia in rats
  publication-title: Toxicol Lett
  doi: 10.1016/j.toxlet.2013.03.002
– volume: 9
  start-page: 145
  issue: 45
  year: 2010
  end-page: 152
  ident: CR27
  article-title: The role of p53 in apoptosis
  publication-title: Discov Med
– volume: 185
  start-page: 1369
  issue: 4
  year: 2011
  end-page: 1373
  ident: CR6
  article-title: Long-term treatment with finasteride improves clinical progression of benign prostatic hyperplasia in men with an enlarged versus a smaller prostate: data from the MTOPS trial
  publication-title: J Urol
  doi: 10.1016/j.juro.2010.11.060
– volume: 37
  start-page: 679
  issue: 2
  year: 2014
  end-page: 688
  ident: CR12
  article-title: Protective effects of seahorse extracts in a rat castration and testosterone-induced benign prostatic hyperplasia model and mouse oligospermatism model
  publication-title: Environ Toxicol Pharmacol
  doi: 10.1016/j.etap.2014.02.001
– volume: 27
  start-page: 668
  issue: 7
  year: 1996
  end-page: 675
  ident: CR4
  article-title: Apoptotic versus proliferative activities in human benign prostatic hyperplasia
  publication-title: Hum Pathol
  doi: 10.1016/S0046-8177(96)90396-2
– volume: 6
  start-page: e20164
  issue: 5
  year: 2011
  ident: CR16
  article-title: Diosgenin, a steroidal saponin, inhibits migration and invasion of human prostate cancer PC-3 cells by reducing matrix metalloproteinases expression
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0020164
– volume: 698
  start-page: 397
  issue: 1-3
  year: 2013
  end-page: 403
  ident: CR19
  article-title: Protective effect of 2-hydroxy-4-methoxy benzoic acid on testosterone induced benign prostatic hyperplasia in Wister rats
  publication-title: Eur J Pharmacol
  doi: 10.1016/j.ejphar.2012.10.028
– volume: 112
  start-page: 432
  issue: 4
  year: 2013
  end-page: 441
  ident: CR3
  article-title: The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH)
  publication-title: BJU Int
  doi: 10.1111/bju.12118
– volume: 132
  start-page: 474
  issue: 3
  year: 1984
  end-page: 479
  ident: CR1
  article-title: The development of human benign prostatic hyperplasia with age
  publication-title: J Urol
– volume: 11
  start-page: 111
  issue: 1
  year: 2006
  end-page: 123
  ident: CR8
  article-title: Emerging drug therapies for benign prostatic hyperplasia
  publication-title: Expert Opin Emerg Drugs
  doi: 10.1517/14728214.11.1.111
– volume: 62
  start-page: 6
  year: 2003
  end-page: 14
  ident: CR2
  article-title: Lower urinary tract symptoms/benign prostatic hyperplasia: fast control of the patient’s quality of life
  publication-title: Urology
  doi: 10.1016/S0090-4295(03)00589-2
– volume: 2012
  start-page: 981675
  year: 2012
  ident: CR15
  article-title: Diosgenin induces apoptosis in HepG2 cells through generation of reactive oxygen species and mitochondrial pathway
  publication-title: Evid Based Complement Alternat Med
– volume: 41
  start-page: 425
  issue: 5
  year: 2002
  end-page: 441
  ident: CR7
  article-title: Drug therapy of benign prostatic hyperplasia syndrome with alpha 1-receptor blockers
  publication-title: Basic principles and clinical results. Urologe A
– volume: 21
  start-page: 19
  year: 2014
  ident: CR25
  article-title: Inhibitors of apoptosis proteins in experimental benign prostatic hyperplasia: effects of serenoa repens, selenium and lycopene
  publication-title: J Biomed Sci
  doi: 10.1186/1423-0127-21-19
– volume: 281
  start-page: 1322
  issue: 5381
  year: 1998
  end-page: 1326
  ident: CR26
  article-title: The Bcl-2 protein family: arbiters of cell survival
  publication-title: Science
  doi: 10.1126/science.281.5381.1322
– volume: 15
  start-page: 646
  issue: 7
  year: 2012
  end-page: 650
  ident: CR17
  article-title: Fraction of macroporous resin from Smilax china L. inhibits testosterone propionate-induced prostatic hyperplasia in castrated rats
  publication-title: J Med Food
  doi: 10.1089/jmf.2011.1968
– volume: 75
  start-page: 199
  issue: 2
  year: 1998
  end-page: 212
  ident: CR23
  article-title: Free radicals, oxidative stress, and antioxidants in human health and disease
  publication-title: J Am Oil Chem Soc
  doi: 10.1007/s11746-998-0032-9
– volume: 27
  start-page: 668
  issue: 7
  year: 1996
  ident: 1666_CR4
  publication-title: Hum Pathol
  doi: 10.1016/S0046-8177(96)90396-2
– volume: 740
  start-page: 379
  year: 2014
  ident: 1666_CR14
  publication-title: Eur J Pharmacol
  doi: 10.1016/j.ejphar.2014.07.026
– volume: 21
  start-page: 19
  year: 2014
  ident: 1666_CR25
  publication-title: J Biomed Sci
  doi: 10.1186/1423-0127-21-19
– volume: 43
  start-page: 49
  issue: 1
  year: 2000
  ident: 1666_CR18
  publication-title: Prostate
  doi: 10.1002/(SICI)1097-0045(20000401)43:1<49::AID-PROS7>3.0.CO;2-J
– volume: 9
  start-page: 145
  issue: 45
  year: 2010
  ident: 1666_CR27
  publication-title: Discov Med
– volume: 158
  start-page: 547
  issue: 2
  year: 1997
  ident: 1666_CR9
  publication-title: J Urol
  doi: 10.1016/S0022-5347(01)64536-1
– volume: 85
  start-page: 328
  issue: 3
  year: 2010
  ident: 1666_CR5
  publication-title: Urol Int
  doi: 10.1159/000315064
– volume: 281
  start-page: 1322
  issue: 5381
  year: 1998
  ident: 1666_CR26
  publication-title: Science
  doi: 10.1126/science.281.5381.1322
– volume: 17
  start-page: 325
  issue: 4
  year: 1999
  ident: 1666_CR22
  publication-title: Cancer Metastasis Rev
  doi: 10.1023/A:1006118628183
– volume: 75
  start-page: 199
  issue: 2
  year: 1998
  ident: 1666_CR23
  publication-title: J Am Oil Chem Soc
  doi: 10.1007/s11746-998-0032-9
– volume: 698
  start-page: 397
  issue: 1-3
  year: 2013
  ident: 1666_CR19
  publication-title: Eur J Pharmacol
  doi: 10.1016/j.ejphar.2012.10.028
– volume: 132
  start-page: 474
  issue: 3
  year: 1984
  ident: 1666_CR1
  publication-title: J Urol
  doi: 10.1016/S0022-5347(17)49698-4
– volume: 185
  start-page: 1369
  issue: 4
  year: 2011
  ident: 1666_CR6
  publication-title: J Urol
  doi: 10.1016/j.juro.2010.11.060
– volume: 34
  start-page: 330
  issue: 3
  year: 2014
  ident: 1666_CR28
  publication-title: J Huazhong Univ Sci Technol [Med Sci]
  doi: 10.1007/s11596-014-1278-0
– volume: 41
  start-page: 425
  issue: 5
  year: 2002
  ident: 1666_CR7
  publication-title: Basic principles and clinical results. Urologe A
– volume: 11
  start-page: 111
  issue: 1
  year: 2006
  ident: 1666_CR8
  publication-title: Expert Opin Emerg Drugs
  doi: 10.1517/14728214.11.1.111
– volume: 112
  start-page: 432
  issue: 4
  year: 2013
  ident: 1666_CR3
  publication-title: BJU Int
  doi: 10.1111/bju.12118
– volume: 6
  start-page: e20164
  issue: 5
  year: 2011
  ident: 1666_CR16
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0020164
– volume: 2014
  start-page: 475876
  year: 2014
  ident: 1666_CR24
  publication-title: Evid Based Complement Alternat Med
  doi: 10.1155/2014/475876
– volume: 14
  start-page: 14301
  issue: 7
  year: 2013
  ident: 1666_CR11
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms140714301
– volume: 27
  start-page: 385
  issue: 4
  year: 2012
  ident: 1666_CR21
  publication-title: Indian J Clin Biochem
  doi: 10.1007/s12291-012-0229-4
– volume: 68
  start-page: 623
  issue: 5
  year: 2007
  ident: 1666_CR13
  publication-title: Phytochemistry
  doi: 10.1016/j.phytochem.2006.10.026
– volume: 78
  start-page: 689
  issue: 4
  year: 2015
  ident: 1666_CR10
  publication-title: J Nat Prod
  doi: 10.1021/np500810c
– volume: 219
  start-page: 160
  issue: 2
  year: 2013
  ident: 1666_CR20
  publication-title: Toxicol Lett
  doi: 10.1016/j.toxlet.2013.03.002
– volume: 2012
  start-page: 981675
  year: 2012
  ident: 1666_CR15
  publication-title: Evid Based Complement Alternat Med
– volume: 15
  start-page: 646
  issue: 7
  year: 2012
  ident: 1666_CR17
  publication-title: J Med Food
  doi: 10.1089/jmf.2011.1968
– volume: 37
  start-page: 679
  issue: 2
  year: 2014
  ident: 1666_CR12
  publication-title: Environ Toxicol Pharmacol
  doi: 10.1016/j.etap.2014.02.001
– volume: 62
  start-page: 6
  year: 2003
  ident: 1666_CR2
  publication-title: Urology
  doi: 10.1016/S0090-4295(03)00589-2
– reference: 23123055 - Eur J Pharmacol. 2013 Jan 5;698(1-3):397-403
– reference: 20193641 - Discov Med. 2010 Feb;9(45):145-52
– reference: 23650937 - BJU Int. 2013 Aug;112(4):432-41
– reference: 20484887 - Urol Int. 2010;85(3):328-33
– reference: 10725865 - Prostate. 2000 Apr 1;43(1):49-58
– reference: 16503830 - Expert Opin Emerg Drugs. 2006 Mar;11(1):111-23
– reference: 24606563 - J Biomed Sci. 2014 Mar 10;21:19
– reference: 21629786 - PLoS One. 2011;6(5):e20164
– reference: 9224349 - J Urol. 1997 Aug;158(2):547
– reference: 25714330 - J Nat Prod. 2015 Apr 24;78(4):689-94
– reference: 12957195 - Urology. 2003 Sep;62(3 Suppl 1):6-14
– reference: 17166529 - Phytochemistry. 2007 Mar;68(5):623-30
– reference: 9735050 - Science. 1998 Aug 28;281(5381):1322-6
– reference: 25062790 - Eur J Pharmacol. 2014 Oct 5;740:379-87
– reference: 12426859 - Urologe A. 2002 Sep;41(5):425-41
– reference: 24082465 - Indian J Clin Biochem. 2012 Oct;27(4):385-8
– reference: 6206240 - J Urol. 1984 Sep;132(3):474-9
– reference: 21334655 - J Urol. 2011 Apr;185(4):1369-73
– reference: 24607683 - Environ Toxicol Pharmacol. 2014 Mar;37(2):679-88
– reference: 22719792 - Evid Based Complement Alternat Med. 2012;2012:981675
– reference: 24939294 - J Huazhong Univ Sci Technolog Med Sci. 2014 Jun;34(3):330-6
– reference: 23846725 - Int J Mol Sci. 2013 Jul 10;14(7):14301-20
– reference: 10453275 - Cancer Metastasis Rev. 1998-1999;17(4):325-30
– reference: 24701239 - Evid Based Complement Alternat Med. 2014;2014:475876
– reference: 8698310 - Hum Pathol. 1996 Jul;27(7):668-75
– reference: 22510101 - J Med Food. 2012 Jul;15(7):646-50
– reference: 23500659 - Toxicol Lett. 2013 May 23;219(2):160-9
SSID ssj0057624
Score 1.7441967
Snippet This study investigated the effect of diosgenin,a natural sapogenin possessing various pharmacological activities,on benign prostatic hyperplasia(BPH) in...
This study investigated the effect of diosgenin, a natural sapogenin possessing various pharmacological activities, on benign prostatic hyperplasia (BPH) in...
SourceID wanfang
proquest
pubmed
crossref
springer
chongqing
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 806
SubjectTerms Animals
Apoptosis
bcl-2-Associated X Protein - metabolism
Diosgenin - pharmacology
Diosgenin - therapeutic use
Glutathione Peroxidase - metabolism
Male
Malondialdehyde - metabolism
Medicine
Medicine & Public Health
Oxidative Stress
Prostate - drug effects
Prostate - metabolism
Prostate-Specific Antigen - blood
Prostatic Hyperplasia - drug therapy
Proto-Oncogene Proteins c-bcl-2 - metabolism
Rats
Rats, Sprague-Dawley
Superoxide Dismutase - metabolism
Tumor Suppressor Protein p53 - metabolism
Title Inhibitory Effect of Diosgenin on Experimentally Induced Benign Prostatic Hyperplasia in Rats
URI http://lib.cqvip.com/qk/85740A/201606/671142946.html
https://link.springer.com/article/10.1007/s11596-016-1666-8
https://www.ncbi.nlm.nih.gov/pubmed/27924509
https://www.proquest.com/docview/1846720523
https://www.proquest.com/docview/1888968145
https://d.wanfangdata.com.cn/periodical/tjykdxxb-e201606005
Volume 36
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAVX
  databaseName: SpringerLINK - Czech Republic Consortium
  customDbUrl:
  eissn: 1993-1352
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0057624
  issn: 1672-0733
  databaseCode: AGYKE
  dateStart: 19970101
  isFulltext: true
  titleUrlDefault: http://link.springer.com
  providerName: Springer Nature
– providerCode: PRVAVX
  databaseName: SpringerLink Journals (ICM)
  customDbUrl:
  eissn: 1993-1352
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0057624
  issn: 1672-0733
  databaseCode: U2A
  dateStart: 20020101
  isFulltext: true
  titleUrlDefault: http://www.springerlink.com/journals/
  providerName: Springer Nature
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELaglRAXVN6hUBmpJ1CkxLEd57hCLQVUTqxUDsiKX7sLlbM0W6n9953JY3cRaCXOmdiRZ-z5JjPzmZBjUVhw-8amhgueclEXcA6KkJZVWZSOWYi3sRv5_Ks8m_LPF-Ji6ONux2r3MSXZndSbZjfwvBj9yhRTXam6T_YFsnmBEU_ZZDx-AT_3N9nKEssqi2JMZf5rCCRUmDdx9hum-9Mx_YU2tzKlXX9PDHWcbbmi0wPyaMCQdNIr_TG55-MT8uB8yJI_JT8-xfnCLDB9Tvt6DdoE6hZNC9ayiLSJdJvY__KWQmAOKnbUwPNZpEtsBUEqVzqHMPVq2bVaghAFc2mfkenpybcPZ-lwjUJqOc9WqfAKgiBXARQqcquE4c4ZWdfOs6p23FQsFNIpcGaWmdKzMg9KBQ9AQgKay0LxnOzFJvqXhHJZK1fbLHdZ4AFvA8wUxHu2BtyC0CEhh-v11MueLkPLEvt1Ky4Tko0rrO3AQI4XYVzqDXcyKkhj1RkqSKuEvFu_Mo63Q_jtqDYNmwQzH3X0zXWrc0RZDP-A75JRqpIq5yIhL3qdr6dElkUO0Coh70cj0MNeb3d9z_FgJxvh1c_bX-7mxmjPkNsP4KZ49V-DHpKHrDNgrKh5TfZWV9f-DeCilTki-5OP37-cHHX74Q7ZzgNX
linkProvider Springer Nature
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEB5BkYAL4tmmpWCknkCR8nAc51ghqi10e-pKvSArtuPdhcpZmq3U_vvO5LG7iGolzpnYkWfs-SYz8xngKEsNun1tQs0zHvKsTPEczFyYF3ma28RgvE3dyONzMZrw75fZZd_H3QzV7kNKsj2p181u6Hkp-hUhpbpC-RieEH8VEeZPkuPh-EX83N1kK3Iqq0zTIZX50BBEqDCr_fQPTve3Y_oHbW5kStv-Hu9KP91wRScv4UWPIdlxp_RX8Kjyr-HpuM-Sv4Gfp34213NKn7OuXoPVjtl53aC1zD2rPdsk9r-6YxiYo4ot0_h86tmCWkGIypXNMEy9XrStlijE0FyatzA5-XbxdRT21yiEhvNoGWaVxCDIFgiF0tjITHNrtShLWyVFabkuEpcKK9GZmUTnVZLHTkpXIZAQiOYil76DHV_7ag8YF6W0pYliGznu6DbASGK8Z0rELQQdAjhYradadHQZSuTUr1twEUA0rLAyPQM5XYRxpdbcyaQgRVVnpCAlA_i8emUYb4vwp0FtCjcJZT5KX9U3jYoJZSX0B3ybjJSFkDHPAtjtdL6aklgWOUKrAL4MRqD6vd5s-56j3k7Wwstfd7_t7a1WVULcfgg3s_3_GvQjPBtdjM_U2en5jwN4nrTGTNU172FneX1THSJGWuoP7Z64BwF3BK8
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3fb9MwELZgSBMviPEzGwMj7QkULXFsx3mc2KoN2MQDlfaCrDi228LkdEsmbf89d03SFoEq8RzHjnxn33e5u-8IORBZBWbfVLHhgsdclBncg8LHeZFnuWUV-NtYjXx-IU_H_POluOz7nDZDtvsQkuxqGpClKbSHc-sPV4VvYIXRE5Yxhr1i9ZA84siTAAo9ZkfDVQxYuutqK3NMscyyIaz5rymQXGFah8k1LP2nkfoLea5FTRe1PsGXYbJmlkZPyZMeT9KjTgF2yAMXnpHt8z5i_pz8OAvTmZlhKJ12uRu09tTO6gY0ZxZoHeg6yf_VPQUnHcRtqYHnk0DnWBaCtK50Ci7rzXxRdgmDKKhO84KMRyffP53GfUuFuOI8aWPhFDhEtgBYlKWVEoZba2RZWseK0nJTMJ9Jq8CwVczkjuWpV8o7ABUSkF3is5dkK9TBvSaUy1LZskpSm3jusTNgosD3q0rAMAgjIrK33E8976gztMyxdrfgMiLJsMO66tnIsSnGlV7xKKOANGagoYC0isiH5SvDfBsGvx_EpuHAYBSkDK6-bXSKiIvh3_BNY5QqpEq5iMirTubLJZFxkQPMisjHQQl0f-6bTd9z0OvJanD78_6Xvbsz2jHk-QPoKXb_a9J3ZPvb8Uh_Pbv4skces4UuY6LNG7LV3ty6fYBLrXm7OBK_AfHSCOs
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Inhibitory+effect+of+diosgenin+on+experimentally+induced+benign+prostatic+hyperplasia+in+rats&rft.jtitle=Journal+of+Huazhong+University+of+Science+and+Technology.+Medical+sciences&rft.au=Chen%2C+Jing&rft.au=Zhang%2C+Huai-fen&rft.au=Xiong%2C+Chao-mei&rft.au=Ruan%2C+Jin-lan&rft.date=2016-12-01&rft.issn=1672-0733&rft.eissn=1993-1352&rft.volume=36&rft.issue=6&rft.spage=806&rft.epage=810&rft_id=info:doi/10.1007%2Fs11596-016-1666-8&rft.externalDBID=NO_FULL_TEXT
thumbnail_s http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F85740A%2F85740A.jpg
http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.wanfangdata.com.cn%2Fimages%2FPeriodicalImages%2Ftjykdxxb-e%2Ftjykdxxb-e.jpg